Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Abramson Cancer Center at Penn Medicine

Status: Enrolling

Conditions: MDS; Leukemia, Acute

Treatments: Other: Cancer-directed Therapy or Best Supportive Care; Diagnostic Test: Frailty Assessment; Procedure: Bone Marrow or Peripheral Blood Graft (BMT)

Study type: Observational

Funder types: Other

Identifiers

NCT03680677

831340 (Other Identifier)

UPCC 06718

Details and patient eligibility

About

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

Enrollment: 20 estimated patients

Sex: All

Ages: 60+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Eligibility Criteria Arm A:

• Age 60 years or older.
• New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.
• Able to consent to the study.

Eligibility Criteria Arm B:

• Age 60 years or older with a hematologic malignancy.
• Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy.
• Able to consent to the study.

Trial design

20 participants in 2 patient groups

Cancer Directed Therapy or Best Supportive Care

Description:

Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care

Treatment:

Diagnostic Test: Frailty Assessment

Other: Cancer-directed Therapy or Best Supportive Care

Transplant

Description:

Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy

Treatment:

Diagnostic Test: Frailty Assessment

Procedure: Bone Marrow or Peripheral Blood Graft (BMT)